MRx0518

DRUG3 trials

Sponsors

4D pharma plc

Conditions

Bladder CancerMelanomaNon Small Cell Lung CancerOncologyPancreatic CancerRenal Cell CarcinomaSolid TumorUrothelial Carcinoma

Phase 1

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

TerminatedNCT03637803

4D pharma plcBladder Cancer, Melanoma, Non Small Cell Lung Cancer +3

Start: 2019-01-10End: 2023-05-08Updated: 2023-06-01

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

TerminatedNCT04193904

4D pharma plcPancreatic Cancer

Start: 2019-12-20End: 2023-05-08Updated: 2023-06-02

Phase 2

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

WithdrawnNCT05107427

4D pharma plcUrothelial Carcinoma

Start: 2022-03-01End: 2023-04-30Updated: 2023-04-18

Related Papers

A phase I study of oral live biotherapeutic MRx0518 with hypofractionated preoperative radiation for resectable pancreatic cancer.

JCO Global Oncology2023-08-012 citations

838 Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation

Regular and Young Investigator Award Abstracts2022-11-011 citations

Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy.

Journal of Clinical Oncology2022-06-011 citations

805 Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours

2020-11-014 citations

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Regular and Young Investigator Award Abstracts2020-11-013 citations

376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors

Regular and Young Investigator Award Abstracts2020-11-012 citations

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.

Journal of Clinical Oncology2019-05-205 citations